Regeneron Pharmaceuticals Financial Statements
NASDAQ: REGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Regeneron Pharmaceuticals revenue and earnings
In fiscal 2025, Regeneron Pharmaceuticals generated $14.34 billion in revenue, up 1.0% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $4.50 billion (+2.1% year over year), for a net margin of 31.4% versus a median of 35.6% in the prior 5 years. Operating margin was 24.9%.
Diluted earnings per share came in at $41.48, up from $38.34. Over the last 5 fiscal years, REGN's revenue has grown at a 11.0% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Regeneron Pharmaceuticals income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.34B | 14.20B | 13.12B | 12.17B | 16.07B | 8.50B | 6.56B | 5.15B | 5.87B | 4.86B |
| Revenue growth (YoY) | +0.99% | +8.27% | +7.76% | -24.26% | +89.14% | +29.58% | +27.44% | -12.37% | +20.82% | +18.44% |
| Cost of Revenue | — | — | — | — | — | — | 402.80M | 237.50M | 202.51M | 194.62M |
| Gross Profit | — | — | — | — | — | — | 6.15B | 4.91B | 5.67B | 4.67B |
| Operating Expenses | — | — | — | — | — | — | 3.94B | 2.37B | 3.59B | 3.34B |
| Research & Development | 5.85B | 5.13B | 4.44B | 3.59B | 2.86B | 2.65B | 2.45B | 1.47B | 2.08B | 2.05B |
| Selling, General & Admin | 2.70B | 2.95B | 2.63B | 2.12B | 1.82B | 1.35B | 1.34B | 1.13B | 1.32B | 1.18B |
| Operating Income | 3.58B | 3.99B | 4.05B | 4.74B | 8.95B | 3.58B | 2.21B | 2.53B | 2.08B | 1.33B |
| Interest Expense | 43.80M | 55.20M | 73.00M | 59.40M | 57.30M | 56.90M | 30.20M | 28.20M | 25.10M | 7.20M |
| Other Income (Expense) | 1.65B | 789.20M | 152.20M | 119.90M | 379.00M | 233.80M | 219.30M | 19.10M | -1.10M | -900.00K |
| Pretax Income | 5.23B | 4.78B | 4.20B | 4.86B | 9.33B | 3.81B | 2.43B | 2.55B | 2.08B | 1.33B |
| Income Tax | 725.80M | 367.30M | 245.70M | 520.40M | 1.25B | 297.20M | 313.30M | 109.10M | 880.00M | 434.30M |
| Net Income | 4.50B | 4.41B | 3.95B | 4.34B | 8.08B | 3.51B | 2.12B | 2.44B | 1.20B | 895.50M |
| Net Income growth (YoY) | +2.09% | +11.61% | -8.87% | -46.28% | +129.86% | +66.05% | -13.44% | +103.95% | +33.84% | +40.79% |
| EPS (Basic) | 43.07 | 40.90 | 37.05 | 40.51 | 76.40 | 32.65 | 19.38 | 22.65 | 11.27 | 8.55 |
| EPS (Diluted) | 41.48 | 38.34 | 34.77 | 38.22 | 71.97 | 30.52 | 18.46 | 21.29 | 10.34 | 7.70 |
| Shares Outstanding (Basic) | 104.60M | 107.90M | 106.70M | 107.10M | 105.70M | 107.60M | 109.20M | 107.90M | 106.30M | 104.70M |
| Shares Outstanding (Diluted) | 108.60M | 115.10M | 113.70M | 113.50M | 112.20M | 115.10M | 114.60M | 114.80M | 115.90M | 116.30M |
| EBITDA | 4.12B | 4.47B | 4.47B | 5.08B | 9.23B | 3.81B | 2.42B | 2.68B | 2.23B | 1.44B |
| Gross Margin | — | — | — | — | — | — | 93.86% | 95.38% | 96.55% | 96.00% |
| Operating Margin | 24.95% | 28.10% | 30.85% | 38.93% | 55.67% | 42.09% | 33.70% | 49.25% | 35.41% | 27.38% |
| Net Margin | 31.41% | 31.07% | 30.14% | 35.64% | 50.25% | 41.35% | 32.26% | 47.50% | 20.41% | 18.42% |
This table shows 10 annual periods of Regeneron Pharmaceuticals's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow REGN's reporting calendar. What is a income statement?